We have begun a new phase in the systemic treatment of BC by focusing on molecular targets that can be attacked, such as the well-known HER-2/neu, which is based upon molecular aberrations in the tumor cells, but not proven to be involved in how tumors metastasize. This evidence concerns the gene ERBB2 and neoplasm.